Conference call for Algeta's $800 million partnering agreement

(Thomson Reuters ONE) - Oslo, Norway, 3 September 2009 - Algeta ASA (OSE: ALGETA), the cancertherapeutics company, signs $800 million (?560m) global agreementwith Bayer for development and commercialization of Alpharadin forbone metastases and retains option for co-promotion and profitsharing in USA.Algeta will present the recently announced partnering agreement withBayer to investors, analysts and the press today at 10:00 CET.Algeta's President and CEO Andrew Kay, CBO Roger Harrison and CFOÿystein Soug will participate.To partake in the conference call, please dial the appropriate numberbelow:800 80 119 (from Norway)+47 23 00 04 00 (from abroad)A presentation is attached to this press release and will be madeavailable on www.algeta.com in the Investors section from 09:00 CET.To access the replay, please dial +47 67 89 40 91. Enter account no.1428 followed by #, then press 1, conference no. 428 followed by #.Press 1 to play. A replay version of the conference call will also beavailable at www.algeta.com For further information, please contactFor AlgetaAndrew Kay, CEO +47 2300 6742 / +47 4840 1360 (mob)ÿystein Soug, CFO +47 2300 7984 / +47 9065 6525 (mob) post(at)algeta.comCitigate Dewe Rogerson(PR Advisor to Algeta)David Dible / Helena Galilee / +44 (0) 207 638 9571Mark Swallow david.dible(at)citigatedr.co.ukhttp://hugin.info/134655/R/1339263/319755.pdfhttp://hugin.info/134655/R/1339263/319758.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 03.09.2009 - 09:04 Uhr
Sprache: Deutsch
News-ID 5443
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 239 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Conference call for Algeta's $800 million partnering agreement"
steht unter der journalistisch-redaktionellen Verantwortung von

Algeta ASA (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Algeta to present at 28th Annual J.P. Morgan Healthcare Conference ...

Algeta announces first US patient randomized in ALSYMPCA phase III study at Tula ...

Oslo, Norway, 11 December - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alph ...

Algeta Results for the Third Quarter 2009 ...

Oslo, Norway, 13 November 2009 - Algeta ASA (OSE: ALGETA), the cancer therapeutics company, today announces its results for the third quarter 2009. An international conference call will take place today at 14:30 CET (details below). Highlights of t ...

Alle Meldungen von Algeta ASA